Nitesh Mani Tripathi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nitesh Mani Tripathi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Anupam Bandyopadhyay
Biomimetic Peptide Engineering Laboratory Department of Chemistry Indian Institute of Technology Ropar Rupnagar Punjab 140001 India
8 shared publications - Arnab Chowdhury
Biomimetic Peptide Engineering Lab, Department of Chemistry, Indian Institute of Technology Ropar, Bara Phool, Rupnagar, India
5 shared publications - Saurav Chatterjee
Indian Institute of Technology Ropar Baraphool
3 shared publications Basab Kanti Das
Biomimetic Peptide Engineering Laboratory, Department of Chemistry
2 shared publications- Neelam Verma
Biomimetic Peptide Engineering Laboratory, Department of Chemistry Indian Institute of Technology Ropar Rupnagar Punjab India
2 shared publications Vinod Gour
Biomimetic Peptide Engineering Laboratory, Department of Chemistry
2 shared publications
Latest Publications
- 22 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (10) , 4923-4938
Conformationally restrained de novo peptides to modulate Skp1–Skp2 interaction of the SCF E3 ligase
Proposed mechanism of first reported peptide-based drugs against the challenging PPI of the Skp1–Skp2 interface.
- 22 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (10) , 4923-4938
Conformationally restrained de novo peptides to modulate Skp1–Skp2 interaction of the SCF E3 ligase
Proposed mechanism of first reported peptide-based drugs against the challenging PPI of the Skp1–Skp2 interface.
- 4 October 2026
- Published by Wiley in Journal of Peptide Science
- Vol. 32 (11) , e70134
Beyond Antibodies: Glypican‐3‐Targeting Peptides for Precision Hepatocellular Carcinoma Theranostics
Glypican‐3 (GPC‐3) is a cell‐surface glycoprotein, highly expressed in hepatocellular carcinoma (HCC) but largely absent in normal adult liver tissues, making it a clinically compelling biomarker and therapeutic target. Although monoclonal antibodies and antibody‐drug conjugates have proven to be GPC‐3‐targeted therapies, their large molecular size, slow pharmacokinetics, and potential immunogenicity limit their diagnostic applications. Peptide ligands offer an attractive alternative owing to their low molecular weight, rapid tumor penetration, favorable clearance profiles, synthetic accessibility, and ease of chemical modification. This topical review highlights the development of linear and cyclic GPC‐3‐binding peptides over the past two decades, developed primarily via phage display, rational optimization, and structure‐guided approaches, enabling PET, SPECT, and fluorescence imaging of HCC in preclinical models. Recent refinements, including albumin‐binding modifications and cyclization strategies, have improved tumor‐to‐liver contrast and in vivo stability. This review summarizes the biological significance of GPC‐3, compares peptides and peptide probes as targeting modalities, and critically analyzes recent advances in linear and cyclic peptide‐based GPC‐3 imaging probes. We also emphasized the importance, current challenges, and future opportunities in AI/ML‐based design of peptide ligands for HCC theranostics.
- 4 October 2026
- Published by Wiley in Journal of Peptide Science
- Vol. 32 (11) , e70134
Beyond Antibodies: Glypican‐3‐Targeting Peptides for Precision Hepatocellular Carcinoma Theranostics
Glypican‐3 (GPC‐3) is a cell‐surface glycoprotein, highly expressed in hepatocellular carcinoma (HCC) but largely absent in normal adult liver tissues, making it a clinically compelling biomarker and therapeutic target. Although monoclonal antibodies and antibody‐drug conjugates have proven to be GPC‐3‐targeted therapies, their large molecular size, slow pharmacokinetics, and potential immunogenicity limit their diagnostic applications. Peptide ligands offer an attractive alternative owing to their low molecular weight, rapid tumor penetration, favorable clearance profiles, synthetic accessibility, and ease of chemical modification. This topical review highlights the development of linear and cyclic GPC‐3‐binding peptides over the past two decades, developed primarily via phage display, rational optimization, and structure‐guided approaches, enabling PET, SPECT, and fluorescence imaging of HCC in preclinical models. Recent refinements, including albumin‐binding modifications and cyclization strategies, have improved tumor‐to‐liver contrast and in vivo stability. This review summarizes the biological significance of GPC‐3, compares peptides and peptide probes as targeting modalities, and critically analyzes recent advances in linear and cyclic peptide‐based GPC‐3 imaging probes. We also emphasized the importance, current challenges, and future opportunities in AI/ML‐based design of peptide ligands for HCC theranostics.
- Open Access
- 11 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
An efficient method for site-selective boronation of peptides and proteins applied in magnified bacterial imaging
Borylated compounds have received tremendous attention in chemical biology and drug design. Motivated by this notion, we develop an efficient methodology for boron incorporation into peptides and proteins via chemoselective conjugation of cysteine residues under catalyst-, additive-, and metal-free conditions. By harnessing the optimum SN2 displacement profile of bromomethyl boronate, we establish a methodology that enables the selective incorporation of methylboronic acid into various peptides, including bioactive constructs, as well as proteins with rapid kinetics (>102 M-1s-1) and excellent conversions at physiological pH. The method also leverages rapid access to bivalent boron conjugates, which, when applied to clinically used antimicrobial peptide UBI(29-41), augment its binding efficacy (40-fold) via covalent capture of the diols on bacterial surface glycans, mainly wall teichoic acid (and thus lipoteichoic acid). Notably, bis-boronated UBI exhibits selective staining of S. aureus over gram-negative bacteria and mammalian cells, alongside a 14-fold increase in serum half-life compared to native UBI.
- 11 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAn efficient method for site-selective boronation of peptides and proteins applied in magnified bacterial imaging
Borylated compounds have received tremendous attention in chemical biology and drug design. Motivated by this notion, we develop an efficient methodology for boron incorporation into peptides and proteins via chemoselective conjugation of cysteine residues under catalyst-, additive-, and metal-free conditions. By harnessing the optimum SN2 displacement profile of bromomethyl boronate, we establish a methodology that enables the selective incorporation of methylboronic acid into various peptides, including bioactive constructs, as well as proteins with rapid kinetics (>102 M-1s-1) and excellent conversions at physiological pH. The method also leverages rapid access to bivalent boron conjugates, which, when applied to clinically used antimicrobial peptide UBI(29-41), augment its binding efficacy (40-fold) via covalent capture of the diols on bacterial surface glycans, mainly wall teichoic acid (and thus lipoteichoic acid). Notably, bis-boronated UBI exhibits selective staining of S. aureus over gram-negative bacteria and mammalian cells, alongside a 14-fold increase in serum half-life compared to native UBI.
- 25 April 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (5) , 829-836
Introducing the Potential Binding Interface between the TRAIL-Mimicking Peptide and DR5 via Alanine Scan
Here we harnessed the unexplored binding interface between the 16-residue peptide (P) agonist and death receptor 5 (DR5). P is a solitary peptide ligand that mimics TRAIL (the natural ligand to death receptor) and is reported to control cancer growth in vivo selectively. We delved into the strategic merging of experimental and in silico structure–activity studies via the alanine scanning mutagenesis of P, wherein the disulfide bond was kept intact for structural integrity. Antiproliferative activity studies with these synthetic mutants on HCT116 cells enabled the mapping of the interaction engagement of each residue. Further, in silico docking and MD simulations led us to interpret and model the 3D interface of the binding site. Notably, Trp1, Leu4, Arg7, Ile8, Gln12, and Arg15 were projected experimentally as “hot-spot” residues crucial for primary interactions with DR5, which is predominantly supported via in silico investigations. This study is pivotal for developing new-generation peptide agonists that induce death receptor-mediated apoptosis.
- 25 April 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (5) , 829-836
Introducing the Potential Binding Interface between the TRAIL-Mimicking Peptide and DR5 via Alanine Scan
Here we harnessed the unexplored binding interface between the 16-residue peptide (P) agonist and death receptor 5 (DR5). P is a solitary peptide ligand that mimics TRAIL (the natural ligand to death receptor) and is reported to control cancer growth in vivo selectively. We delved into the strategic merging of experimental and in silico structure–activity studies via the alanine scanning mutagenesis of P, wherein the disulfide bond was kept intact for structural integrity. Antiproliferative activity studies with these synthetic mutants on HCT116 cells enabled the mapping of the interaction engagement of each residue. Further, in silico docking and MD simulations led us to interpret and model the 3D interface of the binding site. Notably, Trp1, Leu4, Arg7, Ile8, Gln12, and Arg15 were projected experimentally as “hot-spot” residues crucial for primary interactions with DR5, which is predominantly supported via in silico investigations. This study is pivotal for developing new-generation peptide agonists that induce death receptor-mediated apoptosis.
- Open Access
- 24 January 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (2) , 802-810
Introducing Regioselective Disulfide Linkages in Peptides under Pseudodilute Conditions by Harnessing Bro̷nsted Acid-Activated N-Chlorosuccinimide
Methods that assemble multiple peptide disulfide bonds in the solid phase (pseudodilute conditions) are in high demand for synthesizing disulfide-rich peptides. Yet, the existing repertoire of disulfide-forming orthogonal chemistries in the solid phase is often hindered by additional steps for protecting group removals as well as the absolute necessity of rare, customized orthogonal cysteine (Cys) building blocks. We now describe a conceptually new while operationally simple on-resin method for disulfide assembly with widely accessible Cys protecting groups (Trt, Acm, and t Bu) using acid-activated N-chlorosuccinimide (NCS) in a single step. In the process, S- t Bu Cys emerged as a new orthogonal building block for the single-step assembly of the peptide disulfide. In our investigations, 2% TFA-activated NCS offered rapid (∼15 min) and a clean disulfide product in various peptides. Eventually, this novel strategy (2% TFA-NCS) was strategically merged in stepwise cross-linking with our previously described I2/S2O8 2--mediated disulfide assembly protocol to leverage two regioselective disulfide bonds into conotoxin, gomesin, and a de novo sequence within ∼30 min. Invariably, this new method proved highly productive and operationally simple. DFT calculations also support the hypothesis of NCS activation that assists efficient disulfide assembly in crossing a low-lying energy barrier via sulfonium intermediates. This newly developed method for t Bu deprotection and concomitant disulfide assembly in the solid phase should find wide applications in de novo peptide disulfide synthesis.
- 24 January 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (2) , 802-810
Open AccessIntroducing Regioselective Disulfide Linkages in Peptides under Pseudodilute Conditions by Harnessing Bro̷nsted Acid-Activated N-Chlorosuccinimide
Methods that assemble multiple peptide disulfide bonds in the solid phase (pseudodilute conditions) are in high demand for synthesizing disulfide-rich peptides. Yet, the existing repertoire of disulfide-forming orthogonal chemistries in the solid phase is often hindered by additional steps for protecting group removals as well as the absolute necessity of rare, customized orthogonal cysteine (Cys) building blocks. We now describe a conceptually new while operationally simple on-resin method for disulfide assembly with widely accessible Cys protecting groups (Trt, Acm, and t Bu) using acid-activated N-chlorosuccinimide (NCS) in a single step. In the process, S- t Bu Cys emerged as a new orthogonal building block for the single-step assembly of the peptide disulfide. In our investigations, 2% TFA-activated NCS offered rapid (∼15 min) and a clean disulfide product in various peptides. Eventually, this novel strategy (2% TFA-NCS) was strategically merged in stepwise cross-linking with our previously described I2/S2O8 2--mediated disulfide assembly protocol to leverage two regioselective disulfide bonds into conotoxin, gomesin, and a de novo sequence within ∼30 min. Invariably, this new method proved highly productive and operationally simple. DFT calculations also support the hypothesis of NCS activation that assists efficient disulfide assembly in crossing a low-lying energy barrier via sulfonium intermediates. This newly developed method for t Bu deprotection and concomitant disulfide assembly in the solid phase should find wide applications in de novo peptide disulfide synthesis.
- Open Access
- 30 July 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (34) , 13688-13698
Harnessing a bis-electrophilic boronic acid lynchpin for azaborolo thiazolidine (ABT) grafting in cyclic peptides
Chemical modifications of native peptides have significantly advanced modern drug discovery in recent decades. On this front, the installation of multitasking molecular grafts onto macrocyclic peptides offers numerous opportunities in biomedical applications. Here, we showcase a new class of borono-cyclic peptides featuring an azaborolo thiazolidine (ABT) graft, which can be readily assembled utilizing a bis-electrophilic boronic acid lynchpin while harnessing the inherent reactivity difference (>103 M−1 s−1) between the N-terminal cysteine and backbone cysteine for rapid and highly regioselective macrocyclization (∼1 h) under physiological conditions. The ABT-crosslinked peptides are fairly stable in endogenous environments, but can provide the linear diazaborine peptides via treatment with α-nucleophiles. This efficient peptide crosslinking protocol was further extended for regioselective bicyclizations and engineering of α-helical structures. Finally, ABT-grafted peptides were exploited in biorthogonal conjugation, leading to highly effective intracellular delivery of an apoptotic peptide (KLA) in cancer cells. The mechanism of action by which ABT-grafted KLA peptide induces apoptosis was also explored.
- 30 July 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (34) , 13688-13698
Open AccessHarnessing a bis-electrophilic boronic acid lynchpin for azaborolo thiazolidine (ABT) grafting in cyclic peptides
Chemical modifications of native peptides have significantly advanced modern drug discovery in recent decades. On this front, the installation of multitasking molecular grafts onto macrocyclic peptides offers numerous opportunities in biomedical applications. Here, we showcase a new class of borono-cyclic peptides featuring an azaborolo thiazolidine (ABT) graft, which can be readily assembled utilizing a bis-electrophilic boronic acid lynchpin while harnessing the inherent reactivity difference (>103 M−1 s−1) between the N-terminal cysteine and backbone cysteine for rapid and highly regioselective macrocyclization (∼1 h) under physiological conditions. The ABT-crosslinked peptides are fairly stable in endogenous environments, but can provide the linear diazaborine peptides via treatment with α-nucleophiles. This efficient peptide crosslinking protocol was further extended for regioselective bicyclizations and engineering of α-helical structures. Finally, ABT-grafted peptides were exploited in biorthogonal conjugation, leading to highly effective intracellular delivery of an apoptotic peptide (KLA) in cancer cells. The mechanism of action by which ABT-grafted KLA peptide induces apoptosis was also explored.
- 1 July 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (8) , 2766-2772
On-resin synthesis of Lanreotide epimers and studies of their structure–activity relationships
Peptide drugs often accompany epimeric impurities (isomers). Therefore, efficient chemical synthesis of epimers is critical to identify them correctly and investigate their biological activities. Here, we report the rapid synthesis and structure–activity relationship (SAR) studies of eight possible epimers of a somatostatin synthetic analog (SSA), lanreotide (LAN). SPPS and the subsequent on-resin rapid disulfide closure method offered >90% conversion yield for all epimers (P1–P8). Further, we developed an analytical method to separate these epimers, which enabled the profiling of five epimeric impurities in the API, purchased for Somatuline generic formulations. In SAR studies, most LAN epimers revealed compromised antiproliferative activity, while the P7 epimer retained antiproliferative activity similar to LAN API, as supported by in silico SAR studies in detail. Additionally, P7 showed serum stability nearly identical to LAN, suggesting that drug epimers could be a potential API. Current studies will further encourage the development of novel SSA scaffolds.
- 1 July 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (8) , 2766-2772
On-resin synthesis of Lanreotide epimers and studies of their structure–activity relationships
Peptide drugs often accompany epimeric impurities (isomers). Therefore, efficient chemical synthesis of epimers is critical to identify them correctly and investigate their biological activities. Here, we report the rapid synthesis and structure–activity relationship (SAR) studies of eight possible epimers of a somatostatin synthetic analog (SSA), lanreotide (LAN). SPPS and the subsequent on-resin rapid disulfide closure method offered >90% conversion yield for all epimers (P1–P8). Further, we developed an analytical method to separate these epimers, which enabled the profiling of five epimeric impurities in the API, purchased for Somatuline generic formulations. In SAR studies, most LAN epimers revealed compromised antiproliferative activity, while the P7 epimer retained antiproliferative activity similar to LAN API, as supported by in silico SAR studies in detail. Additionally, P7 showed serum stability nearly identical to LAN, suggesting that drug epimers could be a potential API. Current studies will further encourage the development of novel SSA scaffolds.
- 17 November 2021
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 57 (100) , 13629-13640
The modern role of boron as a ‘magic element’ in biomedical science: chemistry perspective
This article discusses in a big-picture manner popular boron chemistries that are a focus in multidisciplinary applications.
- 17 November 2021
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 57 (100) , 13629-13640
The modern role of boron as a ‘magic element’ in biomedical science: chemistry perspective
This article discusses in a big-picture manner popular boron chemistries that are a focus in multidisciplinary applications.